Urelumab (TNFRSF9/CD137) - Research Grid Biosimilar

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb (R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

Homo sapiens / TNFRSF9/CD137 [Homo sapiens]

Unconjugated

Primary Antibodies, Biosimilars

CHO cells

Cancer

>95%

Batch dependent

PBS buffer pH7.5

None

Blue Ice

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

IgG4-kappa

Homo sapiens

BMS-663513